AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

09-30 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-09-02	€0.7400	+0.54%	320,663
26-09-01	€0.7360	+4.69%	259,437
26-08-31	€0.7030	-2.77%	284,132
26-08-28	€0.7230	0.00%	250,769
26-08-27	€0.7230	+1.40%	356,181

Real-time Euronext Paris

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris 11:55:00 2026-09-02 EDT			After hours 15:59:58
0.7400 ^EUR	+0.54%		0.7410	+0.14%

08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT

Market Cap	59.21M 68.63M 55.78M 50.82M 94.99M 6.48B 95.7M 660M 256M 3.31B 258M 252M 10.89B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	59.21M 68.63M 55.78M 50.82M 94.99M 6.48B 95.7M 660M 256M 3.31B 258M 252M 10.89B	EV / Sales 2026 *	49.3x	EV / Sales 2027 *	45.5x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT
08-10	AB Science raises €14.2m
07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-06	AB Science S.A. Announces Board Changes	CI
07-06	AB Science S.A. Announces CEO Changes	CI
07-02	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
06-30	AB Science S.A. announced that it has received ?2.294 million in funding	CI
06-29	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI

08-17	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
08-10	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
08-04	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
07-10	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
07-08	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation : AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript : AB Science

Press Releases : AB Science

News in other languages : AB Science

Quotes and Performance

Price Extremes

Managers and Directors : AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08-24	AB Science : Franchissement de seuils et déclaration d'intention
08-17	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
08-17	AB Science procède au règlement-livraison de son placement privé
08-17	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
08-17	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

1 day	+0.54%
1 week	+0.14%
Current month	+5.26%
1 month	+36.78%
3 months	-21.78%
6 months	-45.27%
Current year	-51.82%

1 week	0.69	0.77
1 month	0.54	1
Current year	0.5	1.61
1 year	0.5	1.68
3 years	0.5	4.46
5 years	0.5	14.53
10 years	0.5	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	2026-07-06
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	65	2021-06-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/20/26	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
2/9/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
2/2/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+0.54%	+0.14%	-45.19%	-77.34%	68.27M
MERCK & CO., INC.	+1.19%	-0.95%	+77.40%	+41.05%	370B
MERCK KGAA	+0.18%	+0.47%	+28.79%	-16.07%	70.44B
HALOZYME THERAPEUTICS, INC.	+1.80%	+2.43%	+49.52%	+168.12%	12.23B
KYOWA KIRIN CO., LTD.	-11.05%	-6.86%	-8.25%	-10.29%	8.79B
SK BIOPHARMACEUTICALS CO., LTD.	-3.03%	+2.25%	-11.94%	+5.12%	5.08B
YUHAN CORPORATION	-1.69%	-2.40%	-27.80%	+21.09%	4.5B
BETTA PHARMACEUTICALS CO., LTD.	-3.55%	-2.68%	-34.57%	-3.62%	3.11B
SUPERNUS PHARMACEUTICALS, INC.	+0.66%	-1.89%	-1.15%	+38.63%	2.54B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.03%	-4.67%	-29.44%	-17.61%	2.05B
Average	-1.63%	-2.21%	-0.26%	+14.91%	47.85B
Weighted average by Cap.	+0.46%	-1.54%	+64.40%	+33.80%

	2026 *	2027 *
Net sales	1.2M 1.39M 1.13M 1.03M 1.93M 131M 1.94M 13.38M 5.19M 67.18M 5.22M 5.11M 221M	1.3M 1.51M 1.22M 1.12M 2.09M 142M 2.1M 14.5M 5.63M 72.78M 5.66M 5.53M 239M
Net income	-	-
Net Debt	-	-